These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36174040)

  • 1. Regulation of Parkinson's disease-associated genes by Pumilio proteins and microRNAs in SH-SY5Y neuronal cells.
    Snoderly-Foster LJ; Olivas WM
    PLoS One; 2022; 17(9):e0275235. PubMed ID: 36174040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic analysis of α-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies.
    Tagliafierro L; Glenn OC; Zamora ME; Beach TG; Woltjer RL; Lutz MW; Chiba-Falek O
    Alzheimers Dement; 2017 Nov; 13(11):1237-1250. PubMed ID: 28431219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single nucleotide polymorphism in the 3'UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease.
    Sotiriou S; Gibney G; Baxevanis AD; Nussbaum RL
    Neurosci Lett; 2009 Sep; 461(2):196-201. PubMed ID: 19540308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovering the 3' UTR-mediated regulation of alpha-synuclein.
    Marchese D; Botta-Orfila T; Cirillo D; Rodriguez JA; Livi CM; Fernández-Santiago R; Ezquerra M; Martí MJ; Bechara E; Tartaglia GG;
    Nucleic Acids Res; 2017 Dec; 45(22):12888-12903. PubMed ID: 29149290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorder.
    Toffoli M; Dreussi E; Cecchin E; Valente M; Sanvilli N; Montico M; Gagno S; Garziera M; Polano M; Savarese M; Calandra-Buonaura G; Placidi F; Terzaghi M; Toffoli G; Gigli GL
    Neurol Sci; 2017 Jul; 38(7):1233-1240. PubMed ID: 28409245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants in the 3'UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression.
    Schmitt I; Wüllner U; van Rooyen JP; Khazneh H; Becker J; Volk A; Kubisch C; Becker T; Kostic VS; Klein C; Ramirez A
    Eur J Hum Genet; 2012 Dec; 20(12):1265-9. PubMed ID: 22617348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus.
    Tatura R; Kraus T; Giese A; Arzberger T; Buchholz M; Höglinger G; Müller U
    Parkinsonism Relat Disord; 2016 Dec; 33():115-121. PubMed ID: 27717584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease.
    Alvarez-Erviti L; Seow Y; Schapira AH; Rodriguez-Oroz MC; Obeso JA; Cooper JM
    Cell Death Dis; 2013 Mar; 4(3):e545. PubMed ID: 23492776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel extended form of alpha-synuclein 3'UTR in the human brain.
    Je G; Guhathakurta S; Yun SP; Ko HS; Kim YS
    Mol Brain; 2018 May; 11(1):29. PubMed ID: 29801501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-599 regulates the development of Parkinson's disease through mediating LRRK2 expression.
    Wu Q; Xi DZ; Wang YH
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):724-731. PubMed ID: 30720180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YY1 binds to α-synuclein 3'-flanking region SNP and stimulates antisense noncoding RNA expression.
    Mizuta I; Takafuji K; Ando Y; Satake W; Kanagawa M; Kobayashi K; Nagamori S; Shinohara T; Ito C; Yamamoto M; Hattori N; Murata M; Kanai Y; Murayama S; Nakagawa M; Toda T
    J Hum Genet; 2013 Nov; 58(11):711-9. PubMed ID: 24026176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of miR-34b and miR-34c enhances α-synuclein expression in Parkinson's disease.
    Kabaria S; Choi DC; Chaudhuri AD; Mouradian MM; Junn E
    FEBS Lett; 2015 Jan; 589(3):319-25. PubMed ID: 25541488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA miR-17-92a-1 cluster host gene (MIR17HG) promotes neuronal damage and microglial activation by targeting the microRNA-153-3p/alpha-synuclein axis in Parkinson's disease.
    Zhang J; Yang Y; Zhou C; Zhu R; Xiao X; Zhou B; Wan D
    Bioengineered; 2022 Feb; 13(2):4493-4516. PubMed ID: 35137671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA.
    Zhang P; Park HJ; Zhang J; Junn E; Andrews RJ; Velagapudi SP; Abegg D; Vishnu K; Costales MG; Childs-Disney JL; Adibekian A; Moss WN; Mouradian MM; Disney MD
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1457-1467. PubMed ID: 31900363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of TRPV1 and TRPA1 Channels Function by Sea Anemones' Peptides Enhances the Viability of SH-SY5Y Cell Model of Parkinson's Disease.
    Kolesova YS; Stroylova YY; Maleeva EE; Moysenovich AM; Pozdyshev DV; Muronetz VI; Andreev YA
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCAAT/enhancer binding protein δ is a transcriptional repressor of α-synuclein.
    Valente T; Dentesano G; Ezquerra M; Fernandez-Santiago R; Martinez-Martin J; Gallastegui E; Domuro C; Compta Y; Martí MJ; Bachs O; Márquez-Kisinousky L; Straccia M; Solà C; Saura J
    Cell Death Differ; 2020 Feb; 27(2):509-524. PubMed ID: 31209363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manganese exposure: Linking down-regulation of miRNA-7 and miRNA-433 with α-synuclein overexpression and risk of idiopathic Parkinson's disease.
    Tarale P; Daiwile AP; Sivanesan S; Stöger R; Bafana A; Naoghare PK; Parmar D; Chakrabarti T; Krishnamurthi K
    Toxicol In Vitro; 2018 Feb; 46():94-101. PubMed ID: 28986288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microarray expression analysis of human dopaminergic neuroblastoma cells after RNA interference of SNCA--a key player in the pathogenesis of Parkinson's disease.
    Häbig K; Walter M; Stappert H; Riess O; Bonin M
    Brain Res; 2009 Feb; 1256():19-33. PubMed ID: 19135032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model.
    Kong Y; Liang X; Liu L; Zhang D; Wan C; Gan Z; Yuan L
    PLoS One; 2015; 10(9):e0137432. PubMed ID: 26361355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson's disease.
    Lahut S; Gispert S; Ömür Ö; Depboylu C; Seidel K; Domínguez-Bautista JA; Brehm N; Tireli H; Hackmann K; Pirkevi C; Leube B; Ries V; Reim K; Brose N; den Dunnen WF; Johnson M; Wolf Z; Schindewolf M; Schrempf W; Reetz K; Young P; Vadasz D; Frangakis AS; Schröck E; Steinmetz H; Jendrach M; Rüb U; Başak AN; Oertel W; Auburger G
    Dis Model Mech; 2017 May; 10(5):619-631. PubMed ID: 28108469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.